FDA Accepts Supplement for STEGLUJAN (Ertugliflozin/Sitagliptin)
The FDA has accepted a supplemental application for STEGLUJAN, a combination of ertugliflozin and sitagliptin.
Asset / Drug
Drug and asset intelligence for STEGLUJAN with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.